Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 22;11(7):594.
doi: 10.3390/life11070594.

Description of a CSF-Enriched miRNA Panel for the Study of Neurological Diseases

María Muñoz-San Martín  1 , Imma Gomez  1 , Albert Miguela  1 , Olga Belchí  1 , René Robles-Cedeño  1 , Ester Quintana  1 , Lluís Ramió-Torrentà  1
Affiliations

Description of a CSF-Enriched miRNA Panel for the Study of Neurological Diseases

María Muñoz-San Martín et al. Life (Basel). .

Abstract

Background: The study of circulating miRNAs in CSF has gained tremendous attention during the last years, as these molecules might be promising candidates to be used as biomarkers and provide new insights into the disease pathology of neurological disorders.

Objective: The main aim of this study was to describe an OpenArray panel of CSF-enriched miRNAs to offer a suitable tool to identify and characterize new molecular signatures in different neurological diseases.

Methods: Two hundred and fifteen human miRNAs were selected to be included in the panel, and their expression and abundance in CSF samples were analyzed. In addition, their stability was studied in order to propose suitable endogenous controls for CSF miRNA studies.

Results: miR-143-3p and miR-23a-3p were detected in all CSF samples, while another 80 miRNAs were detected in at least 70% of samples. miR-770-5p was the most abundant miRNA in CSF, presenting the lowest mean Cq value. In addition, miR-26b-5p, miR-335-5p and miR-92b-3p were the most stable miRNAs and could be suitable endogenous normalizers for CSF miRNA studies.

Conclusions: These OpenArray plates might be a suitable and efficient tool to identify and characterize new molecular signatures in different neurological diseases and would improve the yield of miRNA detection in CSF.

Keywords: CSF; OpenArray; miRNAs; neurological diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
miRNA detection in CSF in TaqMan OpenArray Human Advanced microRNA panels. The number of miRNAs with Cq values (range 15–35) detected in each tested sample was represented in each column. Columns with horizontal stripes represent CSF samples whose initial volume was 300 μL and columns with vertical stripes represent CSF samples whose initial volume was 500 μL.
Figure 2
Figure 2
Most abundant miRNA expression in tissue biopsies by human miRNA tissue atlas. Normalized expression of the most abundant miRNAs in CSF in 30 tissues was retrieved from the human miRNA tissue atlas [20] and the percentage of expression calculated and represented in a heat map.
Figure 3
Figure 3
Evaluation of the optimum number of reference miRNAs for CSF samples according to the geNorm software. Pairwise variation between samples is reduced by the inclusion of additional reference miRNAs. The magnitude of the change in the normalization factor after the inclusion of a ninth additional reference gene implies a value under the recommended cut off of 0.15, showing that the use of eight endogenous controls is optimum for CSF samples.
See this image and copyright information in PMC

References

    1. Misra M.K., Damotte V., Hollenbach J.A. The immunogenetics of neurological disease. Immunology. 2018;153:399–414. doi: 10.1111/imm.12869. - DOI - PMC - PubMed
    1. World Health Organization Mental Health: Neurological Disorders. [(accessed on 28 April 2021)]; Available online: https://www.who.int/news-room/q-a-detail/mental-health-neurological-diso....
    1. Feigin V.L., Nichols E., Alam T., Bannick M.S., Beghi E., Blake N., Culpepper W.J., Dorsey E.R., Elbaz A., Ellenbogen R.G., et al. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–480. doi: 10.1016/S1474-4422(18)30499-X. - DOI - PMC - PubMed
    1. DiLuca M., Olesen J. The cost of brain diseases: A burden or a challenge? Neuron. 2014;82:1205–1208. doi: 10.1016/j.neuron.2014.05.044. - DOI - PubMed
    1. LeFeber J. Advances in Neurobiology. Volume 22. Springer New York LLC; New York, NY, USA: 2019. In Vitro Models of Brain Disorders; pp. 19–49. - DOI - PubMed

LinkOut - more resources